New publication: The Pallas business case - between dream and reality (in Dutch)
An assessment of the plans for a new research reactor which is said to be necessary for the production of medical isotopes. The reactor should be privately funded (expected costs doubled to 600 million euro in a few years) and should enter operation in 2023. Laka raises serious doubts about the business case and fears that government has to step in at a later stage to save the project with public money. The could be a choice if there were no alternatives for the production of medical isotopes, but there is: See the May 2010 Laka report: Medical Radioisotope Production Without A Nuclear Reactor. Here you can find an English summary of the June 2013 report.